PYPD PolyPid Ltd.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1611842 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-17.7%
TTM EPS YoY-57.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-366.3%
ROA-143.8%
ROIC (approx.)-1,290.9%
Asset turnover—
Leverage & solvency
Liabilities / assets50.8%
Debt / equity0.00x
Current ratio1.97x
Interest coverage-37.72x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-26.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $23.81M | $22.81M | $16.15M | $27.99M | $30.55M |
| SG&A expense | $7.18M | $4.27M | $5.52M | $8.01M | $9.61M |
| Operating income | -$32.97M | -$28.03M | -$22.87M | -$38.89M | -$43.15M |
| Interest expense | $874,000 | $1.51M | $1.62M | $1.02M | — |
| Pretax income | -$34.16M | -$28.98M | -$23.80M | -$39.43M | -$42.60M |
| Income tax | $5,000 | $42,000 | $69,000 | $129,000 | — |
| Net income | -$34.17M | -$29.02M | -$23.86M | -$39.56M | -$42.60M |
| EBITDA | -$31.51M | -$26.41M | -$21.05M | -$37.17M | -$42.03M |
| EPS (basic) | 2.09 | 4.91 | 16.99 | 61.09 | 68.27 |
| EPS (diluted) | 2.09 | 4.91 | 16.93 | 61.09 | 68.27 |
| Weighted avg. shares (diluted) | 16.35M | 5.91M | 1.42M | 647,556 | 624,051 |
| Balance sheet | |||||
| Cash & equivalents | $6.40M | $15.64M | $5.31M | $9.14M | $10.46M |
| Current assets | $15.23M | $16.57M | $6.07M | $14.19M | $34.81M |
| PP&E, net | $5.09M | $6.08M | $7.62M | $9.25M | $8.76M |
| Total assets | $22.31M | $25.22M | $15.37M | $25.97M | $44.23M |
| Current liabilities | $7.74M | $12.68M | $7.29M | $8.55M | $8.08M |
| Short-term debt | $988,000 | $6.79M | $4.00M | $4.02M | — |
| Long-term debt | — | $634,000 | $6.38M | $7.57M | — |
| Total debt | — | $7.42M | $10.38M | $11.60M | — |
| Total liabilities | $11.33M | $17.54M | $17.47M | $20.14M | $8.28M |
| Shareholders' equity | $10.97M | $7.68M | -$2.10M | $5.83M | $35.96M |
| Net debt | — | -$8.22M | $5.07M | $2.46M | — |
| Shares outstanding | 18.20M | 10.19M | 1.65M | 669,605 | 18.76M |
| Cash flow statement | |||||
| Operating cash flow | -$27.88M | -$21.96M | -$17.24M | -$34.32M | -$32.39M |
| Capital expenditure | $210,000 | $76,000 | $196,000 | $1.77M | $2.65M |
| Free cash flow | -$28.09M | -$22.04M | -$17.43M | -$36.08M | -$35.04M |
| Investing cash flow | -$6.70M | -$330,000 | $3.80M | $16.57M | $36.90M |
| Financing cash flow | $25.37M | $32.42M | $9.98M | $16.43M | $1.03M |
| Depreciation & amortization | $1.46M | $1.62M | $1.82M | $1.72M | $1.12M |
| Stock-based compensation | $4.85M | $2.82M | $3.39M | $4.31M | $4.75M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.